ASXL1: Several studies showed that ASXL1 somatic mutations are among the most frequent variants in all subtypes of myeloid malignancies including MDS (11–21% cases), AML (5–11%), myeloproliferative neoplasm (MPN), and chronic myelomonocytic leukemia (CMML) (40–50%) (Boultwood et al., 2010; Thol et al., 2011; Fujino and Kitamura, 2020). This evidence concerns the gene ASXL1 and myelodysplastic syndrome.